

ARGENICA APPOINTS VICE PRESIDENT OF BUSINESS DEVELOPMENT

Perth, Australia; 22 NOVEMBER 2023 – Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, is pleased to announce it has appointed Celina Chew as Vice President of Business Development. Celina will work closely with Managing Director Liz Dallimore to assist on all business development activities, including partnering and M&A activities.

Celina is a highly experienced executive. Celina is a qualified lawyer by training having graduated from the University of Western Australia and University of Hong Kong. Celina was named in Forbes’ China 100 Most Powerful Businesswomen Lists of 2017 and 2018.

From 2014 to 2019 Celina was the President for the Greater China area for global life sciences company Bayer. Prior to her role as President, Celina was Head of Bayer’s North ASEAN Region, and also served as General Counsel for Bayer in Greater China for 14 years where she advised Bayer in relation to investments, acquisitions and operations in Greater China. During her time at Bayer Celina worked on a number of commercial deals for the company in Asia where she leveraged her legal and commercial skillset. Bayer is one of the largest healthcare companies in the world and is listed on the Frankfurt Stock Exchange.

Dr Liz Dallimore, **Argenica’s Managing Director**, said: “We are thrilled to have Celina join Argenica to assist with our business development activities. As we start dosing stroke patients in our Phase 2 trial next year and continue to generate exciting preclinical data in other large unmet needs, including Alzheimer’s disease, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE), we are well positioned to enter partnering discussions with global pharmaceutical companies.”

Celina will commence with the Company on 1 December 2023 in a part-time capacity.

This announcement has been approved for release by the Managing Director and Company Secretary.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has recently completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica is now progressing towards a Phase 2 clinical trial in ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions, including in TBI, HIE and Alzheimer's Disease.